215 related articles for article (PubMed ID: 19091547)
21. Design issues of randomized phase II trials and a proposal for phase II screening trials.
Rubinstein LV; Korn EL; Freidlin B; Hunsberger S; Ivy SP; Smith MA
J Clin Oncol; 2005 Oct; 23(28):7199-206. PubMed ID: 16192604
[TBL] [Abstract][Full Text] [Related]
22. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Calvert AH; Plummer R
Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
[TBL] [Abstract][Full Text] [Related]
23. Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution.
Nickolich M; Babakoohi S; Fu P; Dowlati A
Clin Lung Cancer; 2014 May; 15(3):207-12. PubMed ID: 24485231
[TBL] [Abstract][Full Text] [Related]
24. Phase-II trials in osteosarcoma recurrences: A systematic review of past experience.
Omer N; Le Deley MC; Piperno-Neumann S; Marec-Berard P; Italiano A; Corradini N; Bellera C; Brugières L; Gaspar N
Eur J Cancer; 2017 Apr; 75():98-108. PubMed ID: 28219023
[TBL] [Abstract][Full Text] [Related]
25. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.
Francart J; Legrand C; Sylvester R; Van Glabbeke M; van Meerbeeck JP; Robert A
J Clin Oncol; 2006 Jul; 24(19):3007-12. PubMed ID: 16809726
[TBL] [Abstract][Full Text] [Related]
26. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials.
Inker LA; Lambers Heerspink HJ; Mondal H; Schmid CH; Tighiouart H; Noubary F; Coresh J; Greene T; Levey AS
Am J Kidney Dis; 2014 Dec; 64(6):848-59. PubMed ID: 25441438
[TBL] [Abstract][Full Text] [Related]
27. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
Tate Thigpen J
Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
[TBL] [Abstract][Full Text] [Related]
28. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
Kamat AM; Sylvester RJ; Böhle A; Palou J; Lamm DL; Brausi M; Soloway M; Persad R; Buckley R; Colombel M; Witjes JA
J Clin Oncol; 2016 Jun; 34(16):1935-44. PubMed ID: 26811532
[TBL] [Abstract][Full Text] [Related]
29. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
30. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
Bhattacharya S; Fyfe G; Gray RJ; Sargent DJ
J Clin Oncol; 2009 Dec; 27(35):5958-64. PubMed ID: 19826121
[TBL] [Abstract][Full Text] [Related]
31. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.
Lagmay JP; Krailo MD; Dang H; Kim A; Hawkins DS; Beaty O; Widemann BC; Zwerdling T; Bomgaars L; Langevin AM; Grier HE; Weigel B; Blaney SM; Gorlick R; Janeway KA
J Clin Oncol; 2016 Sep; 34(25):3031-8. PubMed ID: 27400942
[TBL] [Abstract][Full Text] [Related]
32. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
Levey AS; Inker LA; Matsushita K; Greene T; Willis K; Lewis E; de Zeeuw D; Cheung AK; Coresh J
Am J Kidney Dis; 2014 Dec; 64(6):821-35. PubMed ID: 25441437
[TBL] [Abstract][Full Text] [Related]
33. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
34. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
35. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
36. Changes in the use of end points in clinical trials for elderly cancer patients over time.
Le Saux O; Falandry C; Gan HK; You B; Freyer G; Péron J
Ann Oncol; 2017 Oct; 28(10):2606-2611. PubMed ID: 28961850
[TBL] [Abstract][Full Text] [Related]
37. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
38. Trial design for evaluation of novel targeted therapies.
Farley J; Rose PG
Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
[TBL] [Abstract][Full Text] [Related]
39. Trends in endpoint selection in clinical trials of advanced breast cancer.
Song SY; Seo H; Kim G; Kim AR; Kim EY
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2403-13. PubMed ID: 27586374
[TBL] [Abstract][Full Text] [Related]
40. Alternate endpoints for screening phase II studies.
Dhani N; Tu D; Sargent DJ; Seymour L; Moore MJ
Clin Cancer Res; 2009 Mar; 15(6):1873-82. PubMed ID: 19276273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
